T1	Participants 0 90	Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei:
T2	Participants 591 819	In a randomized, double-blind, placebo-controlled, Phase I study, 10 evaluable subjects received either three doses of SsWC on Days 0, 14, and 28 (N = 3); five doses of SsWC on Days 0, 2, 4, 6, and 28 (N = 4); or placebo (N = 3)
